Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Pierangelo Veggiotti is active.

Publication


Featured researches published by Pierangelo Veggiotti.


Neuroscience & Biobehavioral Reviews | 2007

Neurofunctional correlates of vulnerability to psychosis: a systematic review and meta-analysis.

Paolo Fusar-Poli; Jorge Perez; Matthew R. Broome; Stefan Borgwardt; Anna Placentino; Eduardo Caverzasi; Mariachiara Cortesi; Pierangelo Veggiotti; Peirluigi Politi; Francesco Barale; Philip McGuire

An understanding of the neurobiological correlates of vulnerability to psychosis is fundamental to research on schizophrenia. We systematically reviewed data from studies published from 1992 to 2006 on the neurocognitive correlates (as measured by fMRI) of increased vulnerability to psychosis. We also conducted a meta-analysis of abnormalities of activation in the prefrontal cortex (PFC) in high-risk and first episode subjects, and reviewed neuroimaging studies of high-risk subjects that used PET, SPECT and MRS. Twenty-four original fMRI papers were identified, most of which involved tasks that engaged the PFC. In fMRI studies, vulnerability to psychosis was associated with medium to large effect sizes when prefrontal activation was contrasted with that in controls. Relatives of patients affected with psychosis, the co-twins of patients and subjects with an At Risk Mental State (ARMS) appear to share similar neurocognitive abnormalities. Furthermore, these are qualitatively similar but less severe than those observed in the first episode of illness. These abnormalities have mainly been described in the prefrontal and anterior cingulated cortex, the basal ganglia, hippocampus and cerebellum.


Neurology | 2003

Spectrum of SCN1A mutations in severe myoclonic epilepsy of infancy

Rima Nabbout; Elena Gennaro; B. Dalla Bernardina; Olivier Dulac; Francesca Madia; Enrico Bertini; Giuseppe Capovilla; Catherine Chiron; G. Cristofori; Maurizio Elia; Elena Fontana; R. Gaggero; Tiziana Granata; Renzo Guerrini; M. Loi; L. La Selva; Maria Luisa Lispi; A. Matricardi; Antonino Romeo; V. Tzolas; D. Valseriati; Pierangelo Veggiotti; Federico Vigevano; L. Vallée; F. Dagna Bricarelli; Amedeo Bianchi; Federico Zara

Objectives: SCN1A mutations were recently reported in several patients with severe myoclonic epilepsy in infancy (SMEI). The authors analyzed SCN1A mutations in 93 patients with SMEI and made genotype-phenotype correlation to clarify the role of this gene in the etiology of SMEI. Methods: All patients fulfilled the criteria for SMEI. The authors analyzed all patients for SCN1A mutations using denaturing high performance liquid chromatography. If a patient’s chromatogram was abnormal, the authors sequenced the gene in the patient and both parents. Results: SCN1A mutations were identified in 33 patients (35%). Most mutations were de novo, but were inherited in three patients. Parents carrying the inherited mutations had either no symptoms or a milder form of epilepsy. A greater frequency of unilateral motor seizures was the only clinical difference between patients with SCN1A mutations and those without. Truncating mutations were more frequently associated with such seizures than were missense mutations. The percentage of cases with family history of epilepsy was significantly higher in patients with SCN1A mutations. Conclusions: Unilateral motor seizures may be a specific clinical characteristic of SMEI caused by SCN1A mutations. Ten percent of SCN1A mutations are inherited from an asymptomatic or mildly affected parent, suggesting that SMEI is genetically heterogeneous. The increased frequency of familial epilepsy indicates that other genetic factors may contribute to this disorder.


Neurology | 2005

Filamin A mutations cause periventricular heterotopia with Ehlers-Danlos syndrome

Volney L. Sheen; An Jansen; Ming-Hui Chen; Elena Parrini; Timothy R. Morgan; R. Ravenscroft; Vijay S. Ganesh; T. Underwood; James S. Wiley; Richard J. Leventer; R. R. Vaid; D. E. Ruiz; G. M. Hutchins; J. Menasha; Judith P. Willner; Y. Geng; Karen W. Gripp; L. Nicholson; Elizabeth Berry-Kravis; Adria Bodell; Kira Apse; Robert Sean Hill; François Dubeau; F. Andermann; James Barkovich; Eva Andermann; Yin Yao Shugart; Pierre Thomas; Maurizio Viri; Pierangelo Veggiotti

Objective: To define the clinical, radiologic, and genetic features of periventricular heterotopia (PH) with Ehlers-Danlos syndrome (EDS). Methods: Exonic sequencing and single stranded conformational polymorphism (SSCP) analysis was performed on affected individuals. Linkage analysis using microsatellite markers on the X-chromosome was performed on a single pedigree. Western blotting evaluated for loss of filamin A (FLNA) protein and Southern blotting assessed for any potential chromosome rearrangement in this region. Results: The authors report two familial cases and nine additional sporadic cases of the EDS-variant form of PH, which is characterized by nodular brain heterotopia, joint hypermobility, and development of aortic dilatation in early adulthood. MRI typically demonstrated bilateral nodular PH, indistinguishable from PH due to FLNA mutations. Exonic sequencing or SSCP analyses of FLNA revealed a 2762 delG single base pair deletion in one affected female. Another affected female harbored a C116 single point mutation, resulting in an A39G change. A third affected female had a 4147 delG single base pair deletion. One pedigree with no detectable exonic mutation demonstrated positive linkage to the FLNA locus Xq28, an affected individual in this family also had no detectable FLNA protein, but no chromosomal rearrangement was detected. Conclusion: These results suggest that the Ehlers-Danlos variant of periventricular heterotopia (PH), in part, represents an overlapping syndrome with X-linked dominant PH due to filamin A mutations.


Neurology | 2008

Evidence of thalamic gray matter loss in pediatric multiple sclerosis

Sarlota Mesaros; Maria A. Rocca; Martina Absinta; A. Ghezzi; Nicoletta Milani; Lucia Moiola; Pierangelo Veggiotti; Giancarlo Comi; Massimo Filippi

Objective: We used voxel-based morphometry (VBM) to assess the pattern of regional gray matter (GM) loss in patients with pediatric multiple sclerosis (MS) and its relation with the Expanded Disability Status Scale (EDSS) score, disease duration, and the extent of T2 lesion load (LL). Methods: From 28 patients with pediatric relapsing-remitting MS (16 girls; mean age = 14.4 years, range = 7 to 16 years) and 21 matched controls, dual-echo and three-dimensional T1-weighted magnetization prepared rapid acquisition gradient echo sequences were acquired. T2 LL was measured using a local thresholding segmentation technique. Data were analyzed using an optimized VBM analysis and statistical parametric mapping. Results: In pediatric patients with MS, mean brain T2 LL was 7.8 mL ± 11.3. Intracranial volume did not differ between patients and controls. Compared to controls, patients with pediatric MS had significant GM loss in the thalamus, bilaterally, which was significantly correlated with T2 LL (r = −0.80 for the right thalamus, r = −0.74 for the left thalamus, p < 0.05, corrected for multiple comparisons). No correlation was found between thalamic GM loss, disease duration, and disability. Conclusions: In patients with pediatric multiple sclerosis (MS), differently from what happens in adult-onset MS, gray matter (GM) atrophy seems to involve the thalamus only, with sparing of the cortex and other deep GM nuclei. The correlation found between atrophy and T2 lesion load suggests transsynaptic and Wallerian degenerations as the most likely substrate of tissue loss in the thalamus of these patients. GLOSSARY: DT = diffusion tensor; EDSS = Expanded Disability Status Scale; FA = flip angle; FOV = field of view; LL = lesion load; GM = gray matter; ICV = intracranial volume; MP-RAGE = magnetization prepared rapid acquisition gradient echo;MS = multiple sclerosis; MT = magnetization transfer; NAWM = normal-appearing white matter; NBV = normalized brain volume; NGM = normalized GM; RR = relapsing-remitting; TE = echo time; TR = repetition time; TSE = turbo spin-echo; VBM = voxel-based morphometry.


Epilepsy Research | 2002

The ketogenic diet in children, adolescents and young adults with refractory epilepsy: An Italian multicentric experience

Giangennaro Coppola; Pierangelo Veggiotti; Raffaella Cusmai; Simona Bertoli; Simonetta Cardinali; Carlo Dionisi-Vici; Mirella Elia; Maria Luisa Lispi; Chiara Sarnelli; Anna Tagliabue; Caterina Toraldo; Antonio Pascotto

PURPOSE This collaborative study by three Italian groups of child neuropsychiatrists was carried on to evaluate the efficacy and safety of the classic 4:1 ketogenic diet as add-on treatment in refractory partial or generalized epilepsy in children, adolescents and young adults. METHODS We performed a prospective add-on study in 56 refractory epilepsy young patients (age 1-23 years, mean 10.4 years), all with both symptomatic and cryptogenic, generalized or partial epilepsies. Child neuropsychiatrists worked with nutritional team for sample selection and patients management. The ketogenic diet was added to the baseline antiepileptic drugs and the efficacy was rated according to seizure type and frequency. During treatment, seizure frequency, side effects, urine and blood ketone levels and other parameters were systematically evaluated. RESULTS Patients have been treated for 1-18 months (mean 5 months). A >50% reduction in seizure frequency was gained in 37.5 and 26.8% of patients after 3 and 6 months, respectively, at 12 months, this number fell by 8.9%. No significant relationship between diet efficacy and seizure or epilepsy type, age at diet onset, sex and etiology of epilepsy was noted. Nevertheless, it seems noteworthy that 64% of our patients with neuronal migration disorders improved on this diet. Adverse effects occurred, mainly in the first weeks of treatment, in 32 patients (57.1%), but were generally mild and transient. In seven patients (12.5%) it was possible to withdraw one to two AED after 3-4 months on ketogenic diet. CONCLUSION This initial experience with the ketogenic diet was effective in difficult-to-treat patients with partial and generalized epilepsies, though its efficacy dropped significantly by 9-12 months.


Epilepsy Research | 2002

Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial

Giangennaro Coppola; Giuseppe Capovilla; Alessandra Montagnini; Antonino Romeo; Maria Spanò; Gaetano Tortorella; Pierangelo Veggiotti; Maurizio Viri; Antonio Pascotto

PURPOSE This study was to evaluate the efficacy and safety of topiramate (TPM) in patients with severe myoclonic epilepsy in infancy (SMEI) and refractory seizures. METHODS We performed a prospective multicentric open label add-on study in 18 patients (age 2-21 years, mean 9 years) with SMEI and refractory seizures of different types. TPM was added to one or two other baseline drugs and the efficacy was rated according to seizure type and frequency. RESULTS TPM was initiated at a daily dose of 0.5-1 mg/kg, followed by a 2-week titration at increments of 1-3 mg/kg/24 h up to a maximum daily dose of 12 mg/kg. After a mean period of 11.9 months (range 2-24 months), three patients (16.7%) had 100% fewer seizures and ten patients (55.5%) had a more than 50% seizure decrease. In no patient there was a seizure worsening. Mild to moderate adverse events were present in four patients (22.2%), represented by weight loss, hypermenorrhoea, renal microlithiasis, nervousness and dysarthric speech. CONCLUSION TPM may be a useful drug in patients with SMEI, being particularly effective against generalized tonic-clonic seizures. Further studies are needed to evaluate the early use of this drug in such a severe syndrome.


Epilepsia | 1999

Continuous Spike-and-Wave Activity During Slow-Wave Sleep: Syndrome or EEG Pattern?

Pierangelo Veggiotti; Francesca Beccaria; Renzo Guerrini; Giuseppe Capovilla; Giovanni Lanzi

Summary: Purpose: We reviewed the electroclinical pictures and clinical characteristics of 32 patients with continuous spike‐and‐wave activity during slow sleep (CSWS) to ascertain to what extent this electroencephalogram (EEG) pattern is associated with the age‐related CSWS syndrome as defined by the International League Against Epilepsy (ILAE) International Classification or with different clinical settings.


Epilepsia | 2011

Cognitive development in Dravet syndrome: a retrospective, multicenter study of 26 patients.

Francesca Ragona; Tiziana Granata; Bernardo Dalla Bernardina; Francesca Offredi; Francesca Darra; Domenica Battaglia; Monica Morbi; Daniela Brazzo; Simona Cappelletti; Daniela Chieffo; Ilaria De Giorgi; Elena Fontana; Elena Freri; Carla Marini; Alessio Toraldo; Nicola Specchio; Pierangelo Veggiotti; Federico Vigevano; Renzo Guerrini; Francesco Guzzetta

Purpose:  To clarify the role of epilepsy and genetic background in determining the cognitive outcome of patients with Dravet syndrome.


Neurology | 2002

Familial periventricular heterotopia Missense and distal truncating mutations of the FLN1 gene

Francesca Moro; Romeo Carrozzo; Pierangelo Veggiotti; Gaetano Tortorella; D. Toniolo; Anna Volzone; Renzo Guerrini

ObjectiveTo examine the clinical and MRI associations in bilateral periventricular nodular heterotopia (BPNH) (MIM # 300049) in two families segregating a missense mutation and a C-terminal deletion of the filamin 1 (FLN1) gene. BackgroundClassical familial BPNH, an X-linked dominant disorder, has been associated with protein truncations or splicing mutations, which tend to cluster at the N-terminal of the FLN1 protein, causing severe predicted loss of the protein function. The clinical syndrome includes symmetrical contiguous nodular heterotopia lining the lateral ventricles, epilepsy, mild retardation to normal cognitive level in affected females, and prenatal lethality in hemizygous boys. MethodsClinical examination, cognitive testing, MRI, mutation analysis (direct sequencing, single-strand conformation polymorphism) in seven patients from two families with BPNH. ResultsIn Family 1, harboring an A > T change in exon 2 (E82V), heterotopic nodules were few, asymmetric, and noncontiguous. Five boys born from affected females had died unexpectedly early in life. In Family 2, harboring an 8 base pair deletion in exon 47 (7627_7634del TGTGCCCC), heterotopic nodules were thick and contiguous. Affected females in both families showed normal to borderline IQ and epilepsy. ConclusionMissense mutations and distal truncations consistent with partial loss of FLN1 function cause familial BPNH with the classical clinical phenotype including epilepsy and mild mental retardation, if any. However, missense mutations have milder anatomic consequences in affected females and are possibly compatible with live birth but short survival of boys.


American Journal of Human Genetics | 2001

Benign Familial Infantile Convulsions: Mapping of a Novel Locus on Chromosome 2q24 and Evidence for Genetic Heterogeneity

Michela Malacarne; Elena Gennaro; Francesca Madia; Sarah Pozzi; Daniela Vacca; Baldassare Barone; Bernardo Dalla Bernardina; Amedeo Bianchi; Paolo Bonanni; Pasquale De Marco; Antonio Gambardella; Lucio Giordano; Maria Luisa Lispi; Antonino Romeo; Enrica Santorum; Francesca Vanadia; Marilena Vecchi; Pierangelo Veggiotti; Federico Vigevano; Franco Viri; Franca Dagna Bricarelli; Federico Zara

In 1997, a locus for benign familial infantile convulsions (BFIC) was mapped to chromosome 19q. Further data suggested that this locus is not involved in all families with BFIC. In the present report, we studied eight Italian families and mapped a novel BFIC locus within a 0.7-cM interval of chromosome 2q24, between markers D2S399 and D2S2330. A maximum multipoint HLOD score of 6.29 was obtained under the hypothesis of genetic heterogeneity. Furthermore, the clustering of chromosome 2q24-linked families in southern Italy may indicate a recent founder effect. In our series, 40% of the families are linked to neither chromosome 19q or 2q loci, suggesting that at least three loci are involved in BFIC. This finding is consistent with other autosomal dominant idiopathic epilepsies in which different genes were found to be implicated.

Collaboration


Dive into the Pierangelo Veggiotti's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Federico Zara

Istituto Giannina Gaslini

View shared research outputs
Top Co-Authors

Avatar

Giancarlo Comi

Vita-Salute San Raffaele University

View shared research outputs
Top Co-Authors

Avatar

Maria A. Rocca

Vita-Salute San Raffaele University

View shared research outputs
Top Co-Authors

Avatar

Massimo Filippi

Vita-Salute San Raffaele University

View shared research outputs
Researchain Logo
Decentralizing Knowledge